-
Mashup Score: 0Biomedical publisher Future Science Group joins Taylor & Francis - 2 month(s) ago
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Biomedical publisher Future Science Group joins Taylor & Francis - 3 month(s) ago
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Categories: General Medicine News, Onc News and JournalsTweet-
🚨 [REMINDER] This Twitter account will be closing on 1st March 2024 🚨 Lung Cancer Management has been acquired by Taylor and Francis. Stay updated @tandfonline Thank you for your support! https://t.co/q7yDd57rxl https://t.co/WDaV2ZxDyO
-
-
Mashup Score: 0Biomedical publisher Future Science Group joins Taylor & Francis - 3 month(s) ago
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Categories: General Medicine News, Onc News and JournalsTweet-
🚨 Important Announcement: Lung Cancer Management has been acquired by Taylor and Francis. Our Twitter account will be closing on 1st March 2024. Stay updated with Taylor&Francis News @tandfnewsroom Thank you for your support! https://t.co/TXkAC3w3bB https://t.co/3x3equQJfI
-
-
Mashup Score: 0LMT 10th Birthday 2022 - 1 year(s) ago
To celebrate Lung Cancer Management 10th Birthday, we are offering a 25% discount on article processing fees until the end of 2022. Submit your article today!
Source: info.future-science-group.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Celebrate Our 10th Birthday With Us🎉🎊 We are welcoming unsolicited article proposals. Make your research article the best one yet and submit your proposal today! Submit Your Article Today & Receive 25% Off Article Processing Fees: https://t.co/R7dEzrDYEa https://t.co/PVdLLquZ9w
-
-
Mashup Score: 3Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC | Future Oncology - 2 year(s) ago
The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer (NSCLC). However, drug resistance inevitably occurs during treatment with EGFR-tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR-TKI, shows a favorable prognosis in T790M-positive NSCLC. Unfortunately, acquired resistance is still a challenge for both patients…
Source: Future OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New #openaccess review article in sister journal @FutureOncol_FSG describes #Immunotherapy-based combination strategies for the treatment of EGFR-TKI-resistant #NSCLC https://t.co/GPXasdpgzF #lungcancer https://t.co/ySvOZPMgxi
-
-
Mashup Score: 0Biopsy frequency and complications among lung cancer patients in the United States | Lung Cancer Management - 4 year(s) ago
Objective: This study aimed to describe the frequency and distribution of biopsy procedures for patients diagnosed and treated for primary lung cancer. Study design: Retrospective cohort study with…
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our latest #openaccess #researcharticle analyses the frequency of #biopsies in #lungcancer patients https://t.co/nYOagbE1IQ https://t.co/pE1dKypLe7
-
-
Mashup Score: 0New platinum chemotherapy in development with promising preclinical results - Oncology Central - 4 year(s) ago
Platinum chemotherapy candidate currently undergoing development is showing reduced toxicity and fewer side effects in preclinical trials.
Source: Oncology CentralCategories: Hem/Oncs, Latest HeadlinesTweet-
Researchers from @UTAustin, @MDAndersonNews and OncoTEX have developed a promising candidate for platinum-based #chemotherapy @OncologyCentral https://t.co/tgCWmyXPAs #cancer
-
-
Mashup Score: 0Lung Cancer Management | Vol 9, No 3 - 4 year(s) ago
We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.× Password Changed Successfully Your…
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Volume 9, Issue 3 of #LungCancer Management is now live! Catch up on all of the #openaccess articles here now: https://t.co/47kkrQQh20 https://t.co/4KMKy8ijJg
-
-
Mashup Score: 0The role of palliative care in the management of patients with lung cancer | Lung Cancer Management - 4 year(s) ago
Palliative care (PC) is the care of patients and their families with serious illness and is rapidly becoming an important part of the care of cancer patients. Patients with advanced lung cancer are…
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In our latest #openaccess #review article @StanfordCancer researchers evaluate #pallativecare in #lungcancer patients https://t.co/XzNaDP9Xb5 #LCSM https://t.co/sMDFMYbOE7
-
-
Mashup Score: 1Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver | Lung Cancer Management - 4 year(s) ago
Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the …
Source: www.futuremedicine.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our latest #openaccess #review from @MontefioreNYC researchers on choosing the best first line therapy in #NSCLC patients https://t.co/pi1YlB08vF https://t.co/m91DK6BLx1
-
🚨 [FINAL REMINDER] This Twitter account will be closing on 1st March 2024 🚨 Lung Cancer Mgmt Jnl has been acquired by Taylor and Francis. For the latest updates, follow @tandfonline https://t.co/orFSGgJhKV https://t.co/gzXhjtxGyX